A contest may develop between liraglutide and a once-a-week formulation of exenatide, Buse said. The longer-lasting exenatide version is expected to reach the U.S. market in about a year. It requires a standard hypodermic needle for injection, while liraglutide can be given through a small, ultrafine needle.
Several other GLP-1 drugs are in trials now and might be approved before long, Buse said. "It will be a great opportunity for patients to have so many choices," he added.
Today's oral medications for diabetes are described by the American Diabetes Association.
SOURCES: Alan Garber, M.D., Ph.D., professor, medicine, biochemistry and cell and molecular biology, Baylor College of Medicine, Houston; John Buse, M.D., president, medicine and science, American Diabetes Association, Atlanta; Sten Madsbad, M.D., professor, endocrinology, University of Copenhagen, Denmark; Sept. 25, 2008, The Lancet, online